uniQure (NASDAQ:QURE) CEO Sells $76,036.44 in Stock

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 6,717 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total value of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares of the company’s stock, valued at $6,574,599.40. This represents a 1.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

uniQure Trading Up 8.9 %

Shares of QURE stock opened at $13.15 on Friday. uniQure has a 1 year low of $3.73 and a 1 year high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock’s 50 day simple moving average is $15.05 and its two-hundred day simple moving average is $9.81. The company has a market cap of $640.73 million, a PE ratio of -2.65 and a beta of 0.38.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 9.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 969 shares during the last quarter. Tudor Investment Corp ET AL grew its stake in uniQure by 5.9% in the fourth quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company’s stock worth $438,000 after purchasing an additional 1,371 shares in the last quarter. Wells Fargo & Company MN grew its stake in uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock worth $217,000 after purchasing an additional 1,503 shares in the last quarter. Northern Trust Corp grew its stake in uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company’s stock worth $1,688,000 after purchasing an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in uniQure by 6.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 3,996 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, February 5th. HC Wainwright boosted their price target on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 12th. Finally, Mizuho upped their price objective on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.